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Abstract
Background: Easy-to-collect epidemiological information is critical for the more accurate estimation of the
prevalence and burden of different non-communicable diseases around the world. Current measurement is
restricted by limitations in existing measurement systems in the developing world and the lack of biometry tests for
non-communicable diseases. Diagnosis based on self-reported signs and symptoms (“Symptomatic Diagnosis,” or
SD) analyzed with computer-based algorithms may be a promising method for collecting timely and reliable
information on non-communicable disease prevalence. The objective of this study was to develop and assess
the performance of a symptom-based questionnaire to estimate prevalence of non-communicable diseases in
low-resource areas.
Methods: As part of the Population Health Metrics Research Consortium study, we collected 1,379 questionnaires
in Mexico from individuals who suffered from a non-communicable disease that had been diagnosed with gold
standard diagnostic criteria or individuals who did not suffer from any of the 10 target conditions. To make the
diagnosis of non-communicable diseases, we selected the Tariff method, a technique developed for verbal autopsy
cause of death calculation. We assessed the performance of this instrument and analytical techniques at the
individual and population levels.
Results: The questionnaire revealed that the information on health care experience retrieved achieved 66.1%
(95% uncertainty interval [UI], 65.6–66.5%) chance corrected concordance with true diagnosis of non-communicable
diseases using health care experience and 0.826 (95% UI, 0.818–0.834) accuracy in its ability to calculate fractions of
different causes. SD is also capable of outperforming the current estimation techniques for conditions estimated by
questionnaire-based methods.
Conclusions: SD is a viable method for producing estimates of the prevalence of non-communicable diseases in
areas with low health information infrastructure. This technology can provide higher-resolution prevalence data,
more flexible data collection, and potentially individual diagnoses for certain conditions.
Keywords: Automated methods, Mexico, Non-communicable diseases, Non-communicable diseases prevalence,
Questionnaire

* Correspondence: bhp3@uw.edu
1
Institute for Health Metrics and Evaluation, University of Washington, 2301
Fifth Ave., Suite 600, Seattle, WA 98121, USA
Full list of author information is available at the end of the article
© 2015 James et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.

James et al. BMC Medicine (2015) 13:15

Background
Non-communicable diseases (NCDs) form a substantial
part of the global burden of disease in both developing
and developed countries, with certain NCDs posing an
equal or greater threat in low-income compared to highincome countries [1]. Mexico, and much of Latin America
in general, have seen a relative increase in their NCD burden in the past 20 years, with conditions such as heart
disease, arthritis, and vision loss steadily increasing in
terms of disability-adjusted life years [1].
Despite the substantial burden of NCDs around the
world, it continues to be difficult to collect accurate information on their prevalence, particularly in areas that lack
consistent or accessible health care. In part, this is due to
inherent limitations in diagnosing these conditions.
While information on some infectious diseases, such as
HIV, malaria, and tuberculosis, can be collected through
biological assays or cultures, such an equivalent does not
exist for certain NCDs. The diagnostic criteria for a condition such as chronic obstructive pulmonary disease
(COPD), for example, require medical resources such
as spirometry or medical knowledge to interpret FEV1/
FVC ratios and differentiate COPD from asthma based
on subtle differences in clinical signs and symptoms.
Moreover, medical diagnostic tests for NCDs, when existent, are frequently more expensive than for infectious
diseases, so surveys tend not to include them; for example,
a rapid diagnostic test for malaria costs less than $1 USD
in most countries [2], whereas the costs to obtain and
measure liver function tests or conduct a 12-lead electrocardiogram are much higher.
Cheaper tests, such as blood pressure and height and
weight, are included in many more surveys than the
more expensive ones like lipids or blood sugar. Despite
these challenges of measuring NCDs, epidemiological
studies endeavor to measure the prevalence of conditions, such as asthma [3], depression [4,5], rheumatoid
arthritis [6], and COPD [7], in many areas of the developing world. However, there are still significant data
gaps and the methods used in these studies have not always been validated against a gold standard clinical and
pathological diagnosis. Thus, given that NCDs contribute significantly to the global burden of disease, and
given that the diagnosis of NCDs requires clinical expertise and medical resources, the analytic question in
this study is whether self-reported signs and symptoms
in a questionnaire survey can be accurately assessed by
data-driven computational models in order to better measure the burden of these diseases.
Using computers to aid in medical diagnosis has been
discussed and explored for decades, ranging from early
articles that examined medical “indices” [8], the possibility of diagnostic “machines” [9,10], and the statistics that
would feed into diagnostic models [11]. More recently,
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computational techniques have been implemented for
clinical tasks including data-based tasks such as identifying arrhythmias in electrocardiogram tracings and interpretation of computed tomography scans, symptom-based
tasks such as predicting maternal morbidity [12], diagnosing asthma [13], and assessing common complaints in an
emergency department [14], and for patient-focused tasks,
e.g., symptom-based questionnaires such as WebMD and
SymCat.
For epidemiological purposes, certain studies measure disease burden based on questionnaire responses,
for example, the World Health Survey [15]. Diagnostic
classification-given questionnaire-based signs and symptoms have been tested in verbal autopsy (VA) research. In
VA studies, interviewers ask family members questions
about the signs and symptoms leading up to a death that
occurred in the household, and physicians or computer
models can be used to classify the estimated cause of
death. The advent of advanced computer techniques for
solving this problem are described elsewhere [16-22], including a comparison of the performance of different
methods and physician-certified VA [23]. This research
has provided compelling evidence that computer algorithms can match or outperform physician-certified VA.
Although this finding refers to deaths occurred in hospital
settings, and further research to test external validity may
be required, it bodes well for the idea that computers can
also be used for diagnosing NCDs in the living.
This study has two main objectives; first, to develop a
questionnaire based on self-reported signs and symptoms
and apply an automated technique to estimate the prevalence of NCDs in low-resource settings and, second,
to assess the performance of both the questionnaire
and the analytical technique at the individual and population level. We refer to this method as “Symptomatic
Diagnosis” (SD).

Methods
Overview of study design

The SD study consisted of two components: data collection and model validation. The data collection portion
consisted of identifying cases of different NCDs in a hospital and then conducting a questionnaire with the patient at a later date. The data were collected in Mexico
as part of the Population Health Metrics Research Consortium (PHMRC) Study [22]. The PHMRC Study is an
offshoot of the Gates Grand Challenge 13 PHMRC Project, an international collaborative focused on developing
better ways to measure health. The model validation component used this validation data to test different approaches to the analytical question of interest.
The SD study developed a questionnaire that focused on
10 NCDs, namely angina pectoris (ICD-10 I20.9), rheumatoid arthritis (ICD-10 M05-M06), cataracts (ICD-10
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H25-H26, H28, Q12.0), asthma (ICD-10 J45), COPD
(ICD-10 J40-J44, J47), symptomatic cirrhosis (ICD10 K70.3, K71.7, K74), vision loss (ICD-10 H54), hearing loss (ICD-10 H90-H91), depression (ICD-10 F32,
F33), and osteoarthritis (ICD-10 M15-M19, M47). These
causes were chosen since they contribute considerably
to the burden of disease in Mexico, and because current methods for collecting prevalence data on these
conditions are expensive and time-consuming. This
questionnaire also collected socio-demographic information. The questionnaire was adapted from the World
Health Survey [15] and the PHMRC Household Survey
[24]. Information on the signs and symptoms of the respondent is collected, but the questionnaire also asks
questions that relate to the respondent’s experience, if
any, with health care providers (health care experience;
HCE). These questions ask about whether the respondent has ever been diagnosed with different conditions,
and whether certain medical procedures or protocols
have occurred. The list of items relevant to ascertain
the presence of a disease in the questionnaire and HCE
indicators is provided in Additional file 1.
Procedure

Data collection involved three stages: identifying cases
for the 10 conditions of interest, identifying controls
who did not suffer from any of the NCDs, and then
implementing the SD questionnaire at the household of
each case and each control.
Cases

A team of trained coders located approximately 1,200
cases (120 of each of the morbid conditions under study)
in 11 public hospitals in the Mexico City area and 120
cases of depression from a psychiatric hospital.
For each condition, a case was defined to be a patient
that a physician had diagnosed with the condition and
who met a specific set of gold standard diagnosis criteria
that was decided on by the PHMRC team. A gold standard diagnosis refers to diagnosis of a specific disease
with the highest level of accuracy possible. This involves
checking that the diagnosis is based on positive results
from a laboratory test or appropriate cabinet and/or
checking that the recording and documentation of the
appropriate symptoms of the disease were observed during the development of clinical records. To be acceptable, the symptoms of the disease must be observed or
documented in a medical record by a physician. The
gold standard criteria for each condition are provided in
Additional file 2.
We only included cases living in Mexico City who had
an address that was identifiable through the hospital records. Once the cases were identified, an interviewer
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visited each household to administer a SD questionnaire to the cases.
Controls

We located a population of controls from the records of
the Automated Detection and Diagnosis Clinic (CLIDDA)
in Mexico City. CLIDDA performs a battery of diagnostic
tests on people who are affiliated with the Instituto de Seguridad y Servicios Sociales para los Trabajadores del
Estado. We defined a control to be someone who attended
the CLIDDA in the last 6 months prior to the data collection, was diagnosed as not having any history of the morbid conditions being studied, was within a similar sex
distribution and age range as the cases, was living in the
urban area of Mexico City, and whose address was locatable from the CLIDDA records. Individuals with an obvious other disease were not included. We identified a
sample of 240 controls. Once the controls were identified
by trained coders from the CLIDDA records, appointments were made, and an interviewer visited each household to administer an SD questionnaire.
Signed informed consent was obtained prior to each
interview. The project was approved by the institutional
review board of the University of Washington and by
the research, ethics, and biosafety committees of the
National Institute of Public Health, Mexico, and participant institutions.
Processing

The SD dataset was processed into a format usable by
statistical models using the same protocol as described
in the PHMRC VA study [22]. Specifically, the duration or
continuous survey items are converted to a dichotomous
“long duration” item using a median absolute deviation estimator, where the item is considered to be endorsed if it
is greater than the long duration cutoff. Cutoffs used in
this study are presented in Additional file 3. Categorical
items are expanded into being separate dichotomous
items for each level or category of the item. For the purpose of clarity, the term “feature” will be used to refer to
the dichotomized (endorsed versus not endorsed) items or
information used by the model/estimation process, while
the term “cause” will be used to refer to “condition” or
“illness” or to healthy controls.
Natural language processing

The SD dataset is composed almost entirely of structured questionnaire items, but free response and text
transcription items are also included. One question on
the survey asked the interviewer to transcribe text found
on any drug containers in the household, and the second
free response item asked the interviewer to write down
any other pertinent information about the interview that
he/she felt was useful.

James et al. BMC Medicine (2015) 13:15

We implemented techniques based on text mining and
natural language processing to capture the “free response”
information [25-29]. We were interested in identifying
text signals that held some diagnostic value and then in
“tokenizing” the free text into data features that could be
used by computational algorithms. For example, for the
text feature “alcohol”, an interview would have a 1 if that
word appeared in the free response section and a 0 if it
did not. In addition, some words or expressions are essentially synonymous for data classification purposes (for
example, “alcohol”, “alcoholism”, and “alcoholic”). In a
process called stemming, we treat the root of the word (in
this case, “alcohol”) as the actual text feature instead of
the entire word itself. To take care of misspellings, mistranslations, or variations in medical terminology we
utilized the dictionary developed for VA analysis that
mapped roughly synonymous words to a single text feature. We utilized in this process the TM package in R [30].
Train-test environment

A critical component of developing and validating data
classification models is constructing an appropriate validation environment. A given model must be “trained”
on a randomly selected portion of the dataset and then
“tested” on an uncontaminated separate portion of the
dataset. In this study we split the entire dataset into 75%
train data and 25% test data, where the components are
sampled by the outcome variable (in this case, the disease). Thus, if there were 100 cirrhosis cases in the full
dataset, then 25 would be sampled into the test data and
75 into the train data. This train-test split is repeated
500 times to conduct 500 simulations and to estimate
uncertainty around the predictive validity estimates.
Previous research in VA has shown that i) predictive
validity is artificially enhanced when test and train composition are similar and ii) the estimated performance of
a method is largely a function of the cause composition
of the test dataset [31]. To solve the second problem,
following Murray et al. [31], we varied the composition
of the test data by resampling with replacement based
on an uninformative Dirichlet distribution.
Models

Four data-driven models for VA classification were tested
and validated as part of the PHMRC study. We were able
to adapt each of these models for use in the SD analysis.
Three of the models – Tariff [18], Simplified Symptom
Pattern [32], and Random Forest [16] – are capable
of diagnosing individual subjects and estimating causespecific mortality fractions (CSMFs), or in our case, causespecific prevalence fractions (CSPF), while the King-Lu
[33] algorithm can only estimate CSMFs (or in our case
CSPFs). The selected method for this analysis was Tariff,
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which has shown a good performance in previous studies
[23] and is described in detail.
Tariff is a simple additive algorithm that uses the calculation of a “tariff” (similar to a Z-score) for each
cause-feature combination in the training data followed
by a summation and ranking function to predict the
most likely causes for each subject in the test dataset.
The Tariff for a given cause-feature combination quantifies how uniquely and strongly predictive a given data
feature is for a given cause. The Tariff for cause i and
feature j is calculated as:
 
xij − Median xj
Tarif f ij ¼
Interquartile Range xj
where Tariffij is the tariff for cause i, feature j, xij is the
fraction of subjects with cause i for which there is a positive response for item j, median (xj) is the median fraction
with a positive response for feature j across all causes, and
interquartile range xj is the interquartile range of positive
response rates for feature j averaged across causes.
For each subject in the SD dataset, we compute summed
Tariff scores for each cause:
Tariff Scoreki ¼

w
X
j ¼ 1

Tarif f ij xjk

The Tariff scores for each cause are ranked across all
subjects, and the top-ranked cause for each subject is
assigned as the diagnosis for that subject.
Analysis

We assessed and compared the capability of the SD
model using the VA performance metrics described by
Murray et al. [31]. SD is capable of i) predicting whether
or not an individual suffers from different NCDs and ii)
estimating the fraction of individuals in a population
who suffer from a given condition. Consequently, the
performance of SD should be quantified in both the individual and population domains.
Chance-corrected concordance

Chance-corrected concordance (CCC) is a measure of a
method’s ability to correctly diagnose a condition in an
individual. However, because random assignment of N
different causes would be correct 1/N times, this metric
must also be adjusted for random chance [31].
The formal calculation of CCC for cause j (CCCj) is:

  
T Pj
1
T P j þFN j − N
1
CCC j ¼
1− N
where TP is true positives, FN is false negatives, and N
is the number of causes or conditions (11 in this study).

James et al. BMC Medicine (2015) 13:15

Page 5 of 12

Cause-specific prevalence fraction (CSPF) accuracy

Results

Following Murray et al. [31], we used CSPF accuracy as a
metric to assess the ability of the questionnaire to estimate
prevalence fractions, analog to CSMF in a verbal autopsy
study. In our case, CSPF accuracy, which is an aggregate
measure across all causes k, is formally defined as:

Symptomatic diagnosis interviews

k 

X


CSPF tj − CSPF jPred 

CSPFAccuracy ¼ 1−

j¼1




2 1 − Min CSPF tj

Where the superscript for CSPF refers to true (“t”) or
predicted (“pred”) cause fractions. The denominator reflects the maximum possible CSPF error in the given
test split:



CSPF Maximum Error ¼ 2 1‐Minimum CSPFj t
Hence, CSPF accuracy can be described as 1 minus the
sum of absolute errors divided by the maximum error. A
CSPF accuracy of 1 would indicate perfect cause fraction
predictions, while 0 would indicate the worst possible
model.
We assessed the performance of SD in the two metrics
described above and in terms of cause fraction absolute
error, which allows for inspection of its performance in
measuring prevalence fractions for each cause. Each type
of validation was conducted across 500 splits of data.
We tested each method under two conditions: with all
data features and with all data features excluding HCE
information.
We also analyzed whether SD methods systematically
over- or underestimate the prevalence fractions. Using
the true and estimated prevalence fractions from 500
splits, we conducted linear regressions where the estimated prevalence fraction was a function of the true
prevalence. Stata, R, and Python were used for all analysis and data management.

We collected 1,379 questionnaires with an accompanying gold standard diagnosis. The number of SD interviews conducted for each of the 10 conditions and for
controls are provided in Table 1. This table also provides
the age and sex distribution by condition and shows that
the project gathered approximately the target number of
interviews or more for each condition and for the control group.
Although questionnaires were analyzed using all of the
different methods mentioned above, this section presents only the results derived from the Tariff method.
Results from analysis using other methods are presented
in Additional file 4 as robustness checks.
Table 2 provides the mean CCC for the Tariff method
across 500 splits, with and without HCE. Overall, CCC
increases with HCE. We calculated the estimated and
true prevalence cause fractions for each test split of data.
These true and estimated cause fractions were used to
calculate absolute errors and CSPF accuracy across 500
splits. Table 2 also provides the median CSPF accuracy
for the Tariff method across 500 splits, with and without
HCE information. As in the case of CCC, accuracy increased with the inclusion of HCE information.
Figures 1 and 2 show CCC and prevalence fraction absolute errors for each specific condition with and without HCE. We observed that depression has high CCC
regardless of whether HCE information is used, while vision loss, cataracts, and osteoarthritis experience lower
performance. Some causes, such as asthma, rheumatoid
arthritis, cirrhosis, or angina, increase their CCC more
than others by the inclusion of HCE information. Prevalence fraction absolute errors are higher in the analysis
without HCE, and are smaller for causes like rheumatoid
arthritis, asthma, and cirrhosis.
In the analysis to check whether SD systematically
over- or underestimates the prevalence fractions, we conducted linear regressions where the estimated prevalence

Table 1 Characteristics of the study participants for each condition
Condition

Number of interviews

Mean age

Standard deviation age

% Male

Angina pectoris

107

62.7

11.9

69%

Asthma

117

42.7

12.8

26%

Chronic obstructive pulmonary disease

108

69.1

11.0

43%

Cataracts

108

68.1

13.4

38%

Cirrhosis

104

51.4

11.3

81%

Depression

100

39.4

15.2

30%

Hearing loss

205

47.3

9.1

29%

Osteoarthritis

107

62.1

11.5

20%

Rheumatoid arthritis

119

52.1

12.3

8%

Vision loss

106

54.9

16.8

39%

Control

198

40.3

6.0

14%

James et al. BMC Medicine (2015) 13:15
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Table 2 Mean chance-corrected concordance and median cause-specific prevalence fraction accuracy across causes
including uncertainty intervals, with and without health care experience (HCE), using the Tariff method
Chance-corrected concordance (CCC)

Cause-specific mortality fractions accuracy

CCC estimate

95% uncertainty interval

CCC estimate

95% uncertainty interval

No HCE

53.4%

(53.2–53.9%)

0.772

(0.765–0.779)

With HCE

66.1%

(65.6–66.5%)

0.826

(0.818–0.834)

fraction was a function of the true one. An illustration of
this analysis for angina pectoris with HCE is provided in
Figure 3a. This figure and associated coefficient and intercept illustrate how the SD for this cause tends to slightly
underestimate the prevalence of angina pectoris, except
for very low true prevalence fractions. In contrast, the
equivalent scatterplot in Figure 3b for hearing loss shows
more overestimation when the true prevalence fraction is
0 but a general systematic underestimation for larger prevalence fractions.

Cross-classification and cause aggregation

We found that the SD achieved high CCC for the causes of
angina pectoris, depression, and cirrhosis. However, vision
loss and osteoarthritis experienced lower performance. To
explore if there was some cross-classification between
vision loss with cataracts due to the similar clinical presentation of these conditions, we used cross-classification or
“confusion” matrices. An example of a confusion matrix
for a single split (prior to undergoing the Dirichlet-based
resampling) is shown in Additional file 5. This confusion

Figure 1 Cause-specific chance-corrected concordance with and without health care experience.

James et al. BMC Medicine (2015) 13:15
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Figure 2 Cause-specific prevalence fraction absolute errors with and without health care experience.

matrix shows how 8 out of 24 true vision loss cases were
correctly classified as vision loss, but 8 were misclassified
as cataracts. Out of 27 true cataracts cases, 10 were correctly classified as cataracts, but 5 were misclassified as
vision loss.
This investigation of cause assignments indicated that
there could be considerable cross-classification but also
that the features most strongly associated with vision
loss or cataracts had a much weaker association than
other feature-cause combinations. This suggests the possibility of increasing performance by combining similar
causes. So, instead of differentiating between vision loss
and cataracts, we generated a combined category of “vision loss or cataracts.” We measured the effect of this
aggregation on performance and found that overall CCC
increased by approximately 3% in absolute terms and
that CSPF accuracy increased by 0.032 in absolute terms
(Table 3). The prevalence fraction absolute error and
CSPF accuracy for the nine-cause aggregation is shown
in Additional file 6.

Discussion
The PHMRC SD study presents a novel source of data
and an innovative application of VA research to computational estimation of NCD burden. The study identified
cases of 10 NCDs that had been diagnosed with gold
standard criteria and then conducted a questionnaire with
over 100 patients for each condition. The questionnaire
was designed to estimate prevalence using data-driven

methods, specifically the Tariff method, which has been
validated in VA studies. By applying Tariff to the PHMRC
dataset, we sought to demonstrate that the questionnairebased approach of SD may be a valuable asset to future
epidemiological research concerning the burden of NCDs.
We further simulated the application of Tariff in the field
by testing the performance with the inclusion/exclusion of
HCE information, which allowed us to determine the viability of using Tariff in areas with no health care, and by
testing performance in samples of test data with random
cause compositions. The results of the study can thus be
considered robust due to i) the gold-standard validation of
the questionnaire responses, ii) the calculation of predictive validity in various test data compositions, and iii) comparisons with the performance of current epidemiological
measurement approaches.
We observed that the Tariff method applied to the SD
questionnaire is a promising approach for collecting
prevalence data on the NCDs outlined in this study.
Tariff was capable of estimating prevalence fractions
within 3% for each condition. Additionally, 5 of the 11
conditions have a CCC of over 60%. Estimation of prevalence fractions within 3% for these chronic conditions
would allow for higher resolution epidemiological information in areas with sparse data, and for the conditions
with high performance in terms of CCC, this technology could be used for diagnoses in the field without
requiring extensive medical expertise or other tools or
resources.

James et al. BMC Medicine (2015) 13:15
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Figure 3 True and estimated prevalence fractions using the Tariff Method with health care experience for 500 splits for (a) angina
pectoris and (b) hearing loss.

James et al. BMC Medicine (2015) 13:15
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Table 3 Chance-corrected concordance and cause-specific
prevalence fraction accuracy for nine-cause aggregation
using the Tariff Method, with and without health care
experience (HCE)
Chance-corrected
concordance (%)

Cirrhosis

No
HCE (%)

With
HCE (%)

82.4

90.6

Depression

87.5

88.7

Angina pectoris

80.1

84.1

Asthma

68.9

76.4

Arthritis

63.4

70.3

Vision loss or cataracts

57.0

57.4

Chronic obstructive pulmonary disease

41.6

49.5

Hearing loss

47.1

47.9

Control

56.5

57.8

Mean chance-corrected concordance (%)

65.0

69.2

Median cause-specific prevalence fractions accuracy

0.842

0.858

While Tariff demonstrated accurate results in measuring certain conditions, it was found to be less accurate
in others. The lower performance of Tariff in identifying
vision loss, cataracts, and osteoarthritis can be explained
partially through cross-classification error, but the relatively poor performance of hearing loss with Tariff may
be a surprising result since it seems reasonable that hearing loss patients would express somewhat salient signs
and symptoms compared with other conditions. The analysis of endorsement rates of all features by true cause
showed that one of the obstacles in diagnosing hearing
loss based on this questionnaire derives from a lack of
items with a high endorsement rate for hearing loss but
not for other causes. For example, one item asks, “Have
you ever had your hearing checked by a provider?” While
the endorsement rates for hearing loss are high (91.2%)
for this item, cases with the other conditions also endorse
this item at a fairly high frequency (82.2% of the controls
and 71.8% of the asthma cases). In contrast, causes that
had better performance tend to have an item that has a
high endorsement rate for that cause but not for others.
For example, the question “Have you had a period lasting
several days when you lost interest in most things that you

usually enjoy such as pastimes, relationships, or work?”
has a 90% endorsement rate among depression cases, but
no higher than 30.3% endorsement for other causes.
In our literature-based comparison to current methods,
we observed that Tariff was capable of matching or outperforming the questionnaire-based methods such as the
Rose questionnaire and the composite international diagnostic interview (CIDI) depression questions in terms of
prevalence estimation (Table 4). The SD questionnaire essentially includes the Rose questionnaire, CIDI depression
questions, and the World Health Survey asthma questions. Since, in theory, the positive endorsement of the
items for these questions should essentially ensure correct
diagnosis, it may be surprising that the data-driven SD
methods can achieve higher performance than these current approaches. That is, we did not need to “tell” Tariff
that endorsement of the Rose questions indicates angina
pectoris; rather, Tariff determined those relationships on
its own. The result in some ways parallels the finding in
VA research that computational methods can compete
with and possibly outperform physician-certified autopsy.
Current estimation of COPD, rheumatoid arthritis,
osteoarthritis, vision loss, hearing loss, cirrhosis, and cataracts can be undertaken with a high level of accuracy in
a clinical setting, but their diagnosis requires specialized
diagnostic equipment and extensive medical training. Certainly, it is desirable to collect the most accurate information possible, but access to these tools and resources is
not possible in all areas of the world. Furthermore, SD has
the unique advantage of being able to collect information
on every condition after conducting a single interview.
The alternative approaches of carrying diagnostic equipment for each of these conditions or conducting multiple
cause-specific diagnostic surveys in parallel seems very
implausible. As discussed in the introduction, this is an
unfortunate paradox since the areas lacking these resources are also likely the areas that have the worst health.
SD, in this regard, is a valuable alternative to collecting
more refined information in a resource-poor setting. A
household survey can be conducted virtually anywhere in
the world. Currently, Demographic and Health Surveys
and World Health Surveys cover areas of the world
such as Sudan, Cote d’Ivoire, and Democratic Republic of
Congo, for example. If access to the tools and expertise to

Table 4 Absolute errors in prevalence estimates from SD method to literature-based approaches
Condition

Test

Absolute error (95% CI)

Symptomatic diagnosis-Tariff
method with health care experience
absolute error (95% CI)

Asthma

World Health Survey (WHS): Doctor (MD) diagnosis (Dx) [34]

0.023 (0.020, 0.025)

0.014 (0.012, 0.016)

WHS MD Dx OR asthma medications (Rx) [34]

0.023 (0.020, 0.025)

WHS MD Dx OR asthma Rx OR wheezing/whistling attacks [34]

0.092 (0.087, 0.095)

Angina pectoris

Rose questionnaire [35,36]

0.082 (0.073, 0.088)

0.020 (0.018, 0.022)

Depression

Composite international diagnostic interview questionnaire [37]

0.059 (0.054, 0.064)

0.016 (0.015, 0.017)

James et al. BMC Medicine (2015) 13:15

diagnose these conditions in these areas is unavailable,
then SD-based epidemiology could be a practical alternative. The use of SD methods in low-resource or inaccessible areas to identify and focus attention on the chronic
disease burden could also help address the aforementioned paradox. Furthermore, training field workers to
conduct an SD survey seems likely to be less expensive
than making available the resources to diagnose all of the
conditions outlined in this study. Cumulatively, this flexibility makes SD a compelling alternative strategy for
measuring the burden of these conditions.
Limitations

Our study had some inherent limitations. One of the main
limitations and questions in VA research is that questionnaire responses for deaths that occur in the community
could be systematically different than the responses from
deaths that occur in hospitals. If the response patterns are
sufficiently different, then the computational methods
could perform differently than expected when they are implemented in the field. However, this limitation, which applies also to SD, is essentially a normative question. It is
not possible to develop data-driven models unless this
limitation is accepted, and as previous research in VA
has shown, data-driven models can match or outperform
expert-based models [23]. To deal with this limitation, we
drew 500 samples with different prevalence of NCDs
under study from our study sample, and attempted to
simulate cases where the respondent did not have access
to health care by conducting analyses in which we withheld HCE features.
A second limitation is that the study did not include
individuals whose address could not be found, and this
may potentially introduce a bias if individuals who were
not found are systematically different in their socioeconomic status or other characteristics from the ones who
were located. The main reason for not locating cases
was that the patient provided the address of a relative to
have access to some hospitals in Mexico City; therefore,
we do not think that it is likely that there are clear differences in the socioeconomic status of these individuals.
However, it is possible that the study may exclude some
individuals from lower socioeconomic status that could
not be located.
Since prevalence data are sparse in many areas of the
world, it is important to consider the potential implementation of the SD methods outlined in this study in
countries besides Mexico. The 10 NCDs considered in
this study are also highly prevalent in areas of Africa and
Asia, and this consideration raises the question if there
exist systematic cultural variations in questionnaire response data. It seems plausible that response patterns
for something as sensitive as a medical interview will have
cultural idiosyncrasies. This limitation can be addressed
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by further collection of validated SD questionnaire responses in other countries. In fact, additional validated SD
questionnaire response data would strengthen the performance of the existing models. Furthermore, the computational SD methods can readily be retrained on any
further validation data collected, though similar to VA,
the general SD approach will be strongest if a central data
repository is maintained such that the central Tariff matrix
can be continually updated.
Finally, while the inclusion of healthy controls is generally a strength in this study, it is possible that the
healthy controls can be ill with minor conditions. The
inclusion of these controls is important, however, because it allows for a model to predict that a person does
not suffer from a given condition despite possibly presenting some of the signs and symptoms associated with
that condition. For example, 50% of the controls report
a non-productive cough, which is not a dramatically
lower endorsement rate than asthma, in which 58% of
cases reported a non-productive cough. The inclusion of
controls highlights one of the important differences between SD and VA: every person who dies has an underlying cause of death, but not every living person has an
underlying illness. There were also some differences in
the characteristics of the health controls compared to
the rest of the study participants as shown on Table 1;
specifically, the controls tend to be slightly younger and
are more frequently female than the other participants.
Future implementation

The central question for future implementation of SD
methods is whether this method provides adequate accuracy and usability to be used for epidemiologic data
collection. Certainly, in the hierarchy of epidemiological
data, self-reported signs and symptoms in an interview
setting has historically been considered relatively lowerquality data; however, one of the important findings in
this study was that the methods and criteria used in
traditional epidemiologic studies of these diseases was in
fact less accurate than the methods tested here. Thus,
this study provides promising evidence that self-reported
signs and symptoms combined with techniques such as
the Tariff method may be more valuable than previously
understood. Regardless, it will be important to further
validate the performance of SD methods, particularly by
using further cross-validation with data collected from
outside this study. Similarly, while this study focused on
selected NCDs in one country, it will be important to
conduct further research both in other countries and
with other conditions in order to generalize the capabilities of SD. This will be particularly important when it
comes to NCDs with more protean clinical presentations, in areas where it is more difficult to collect data,
and in patients who may have multiple comorbidities.
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Ideally, future work will further develop the capabilities
of SD in assessing the prevalence of other NCDs in
other areas of the world, contributing to a better understanding of the burden of NCDs globally.
With these considerations, the implementation of the
tool developed in this study requires two further steps
for interested users. The first step is facilitating the implementation of the questionnaire itself. The questionnaire is provided in this study and can hypothetically be
used as-is. However, current work in VA is moving toward using tablet devices that can use questionnaire
software such as Open Data Kit Collect to facilitate data
collection. Options such as geotagging, digital imagery,
and improved instrument clarity/organization make this
an even more compelling data collection approach. The
second required step is developing a user-friendly software package that readily conducts the method described in this study. Reducing these barriers will facilitate
more rapid use of the methods outlined in this study to
improve the collection of health information for NCDs.

Conclusions
The SD study had the goal to develop better instruments
and methods for measuring population health, particularly in resource-poor settings where clinicians are not
available to assist in diagnosis of NCDs. To this end, the
study was a success in that it found that the Tariff method could accurately measure the prevalence of several
important conditions. This study provides a promising
way to improve strategies for population health measurement and to produce instruments that are scientific, standardized, and widely applicable across different resourcepoor settings. Although more work is required to test
this method in other NCDs and in different settings,
the SD questionnaire combined with the Tariff method,
has the potential to help researchers better measure the
burden of NCDs and to additionally enable policymakers
and researchers to help address persistent inequities in
health outcomes in both the developed and the developing world.
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